Mimedx (MDXG) Acquisitions (2011 - 2026)

Mimedx (MDXG) posted Acquisitions of $5.0 million for Q1 2026, up 63.19% sequentially from $3.1 million in Q3 2025.

Mimedx (MDXG) Acquisitions (2011 - 2026) Analysis & Trends

Mimedx has reported Acquisitions for 5 years, with the latest figure at $5.0 million in Q1 2026.

Quarterly Acquisitions changed N/A year-over-year to $5.0 million in Q1 2026, while the trailing twelve-month figure through Jun 2026 was $8.1 million (up 152.32% YoY) and the FY2025 annual result came in at $3.8 million, down 52.12% from the prior year.
Acquisitions improved to $5.0 million in Q1 2026 per MDXG's latest filing, from $3.1 million in the prior quarter.
Over five years, Acquisitions peaked at $5.0 million in Q1 2024 and troughed at $366000.0 in Q2 2024.
A 3-year average of $2.8 million and a median of $2.8 million in 2024 frame the typical range for Acquisitions.
The widest YoY moves for Acquisitions: up 91.26% in 2025, down 91.26% in 2025.
Over 3 years, Acquisitions stood at $2.5 million in 2024, then gained by 22.76% to $3.1 million in 2025, then surged by 63.19% to $5.0 million in 2026.
According to Business Quant data, Acquisitions over the past three periods registered $5.0 million, $3.1 million, and $700000.0 for Q1 2026, Q3 2025, and Q2 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Acquisitions (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	-
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	-
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	Mimedx	622.24 Mn	486.40 Mn	44.38 Mn	-

Download Data